Research progress on biomarkers of irritable bowel syndrome

doi:10.16352/j.issn.1001-6325.2023.03.500

Abstract

Abstract: Irritable bowel syndrome (IBS) is a functional gastrointestinal disease, and its diagnostic criteria has been based on clinical profile. There are various biomarkers associated with IBS.This paper reviews the relationship between IBS and those biomarkers like mean platelet volume (MPV), red blood cell distribution width (RDW), neutrophil/lymphocyte ratio (NLR), high-sensitivity C-reactive protein (HS-CRP), C-reactive protein (CRP), resolvin D1 (RvD1), interleukin 6 (IL-6), interleukin 8(IL-8), tumor necrosis factor-α(TNF-α), fecal calprotectin (FCP), fecal lactoferrin (LF).The research and clinical application of valuable biomarkers for the diagnosis of IBS may make the diagnosis of IBS more accurate and faster,with less application of colonoscopy.

Key words: irritable bowel syndrome, serum biomarker, fecal biomarker, Roman standard

CLC Number:

R574.4

ZHENG Xingjian, RAN Xue, REN Ziyue, DAI Chibing. Research progress on biomarkers of irritable bowel syndrome[J]. Basic & Clinical Medicine, 2023, 43(3): 500-504.

References

[1]Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, et al. Irritable bowel syndrome-from etiopathogenesis to therapy[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018, 162: 1-9.
[2]Nakov R, Snegarova V, Dimitrova-Yurukova D, et al. Biomarkers in irritable bowel syndrome: biological rationale and diagnostic value[J]. Dig Dis, 2022, 40: 23-32.
[3]Selim A, Saad Salem S, Albasher N, et al. Irritable bowel syndrome and coping strategies: a cross-sectional study for identifying psychological alarms and factors related to coping in riyadh, saudi arabia[J]. Clin Nurs Res, 2022,31:144-154.
[4]Grabauskas G, Wu X, Gao J, et al. Prostaglandin E(2), produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice[J]. Gastroenterology, 2020,158:2195-2207.
[5]赵军梅, 袁丽萍, 蔡洁, 等. 肠易激综合征患儿肠道菌群可促进小鼠肠道酸敏感离子通道蛋白的表达[J]. 基础医学与临床, 2020,40:173-177.
[6]Mars R, Yang Y, Ward T, et al. Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome[J]. Cell, 2020,182:1460-1473.
[7]Masuy I, Pannemans J, Tack J. Irritable bowel syndrome: diagnosis and management[J]. Minerva Gastroenterol Dietol, 2020,66:136-150.
[8]Vaghari-Tabari M, Moein S, Qujeq D, et al. Sensitivity and specificity of mean platelet volume as a laboratory marker for irritable bowel syndrome: Can it be added to Rome criteria[J]. Afr J Lab Med, 2020,9: 1001.doi:10.4102/ajlm.v9il.1001.
[9]Korniluk A, Koper-Lenkiewicz OM, Kamińska J, et al. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions[J]. Mediators Inflamm, 2019,2019:9213074.
[10]Güçlü M, Ağan AF. Relationship of peripheral blood neutrophil to lymphocyte ratio and irritable bowel syndrome[J]. Turk J Med Sci, 2017, 47: 1067-1071.
[11]Benvenuti E, Pierini A, Gori E, et al. Neutrophil-to-lymphocyte ratio (NLR) in canine inflammatory bowel disease (IBD)[J]. Vet Sci, 2020,7:141.doi:10.3390/vetsci7030141.
[12]Hod K, Dickman R, Sperber A, et al. Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome[J]. Neurogastroenterol Motil, 2011. 23: 1105-1110.
[13]张瑜, 张露, 李双, 等. 超敏C反应蛋白在不同亚型肠易激综合征的表达及其与炎症因子的相关性[J]. 世界华人消化杂志, 2020,28:782-788.
[14]余沛君, 方晨, 梅咏玉,等. 消退素D1调节巨噬细胞自噬对实验性结肠炎小鼠的影响[J]. 安徽医科大学学报, 2020. 55: 860-864.
[15]谭立军. 肠易激综合征患者CRP水平及其与幽门螺杆菌感染的相关性[J]. 中国热带医学, 2013, 13: 1143-1145.
[16]Karatay E, Utku ÖG. Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome[J]. Turk J Gastroenterol, 2020, 31: 113-119.
[17]Hirano T. IL-6 in inflammation, autoimmunity and cancer[J]. Int Immunol, 2021, 33: 127-148.
[18]Mitselou A, Grammeniatis V, Varouktsi A, et al. Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease[J]. Intest Res, 2020, 18: 115-120.
[19]Seyedmirzaee S, Hayatbakhsh MM, Ahmadi B, et al. Serum immune biomarkers in irritable bowel syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40: 631-637.
[20]Bennet S, Palsson O, Whitehead WE, et al. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics[J]. Neurogastroenterol Motil, 2018, 30: e13378.doi:10.1111/nmo.13378.
[21]Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin[J]. Crit Rev Clin Lab Sci, 2019, 56: 307-320.
[22]Nemakayala DR, Cash BD. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go[J]. Curr Opin Gastroenterol, 2019, 35: 58-62.
[23]Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation[J]. Sci Rep, 2017, 7: 2669.doi:10.1038/s41598-017-02835-5.
[24]Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D)[J]. Gastroenterology, 2019, 157: 859-880.